UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15 (d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
Report (Date of earliest event reported) March
29, 2005
ADVENTRX
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
(State or
other jurisdiction of incorporation)
|
001-32157
(Commission
File Number) |
|
84-1318182
(IRS
Employer Identification No.) |
6725
Mesa Ridge Road, Suite 100
San
Diego, California 92121
(Address
of principal executive offices) (Zip Code)
(858)
552-0866
(Company’s
telephone number, including area code)
Item
8.01. Other Events.
On March
29, 2005, the Company announced certain developments regarding its planned
CoFactor Phase III trial for pancreatic cancer in the European Union.
The press
release issued by the Company on March 29, 2005 with respect to these matters is
included with this report as an exhibit.
Item
9.01. Financial Statements and Exhibits.
(c) The
exhibit list required by this item is incorporated by reference to the Exhibit
Index filed as part of this report.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
|
|
| |
ADVENTRX
Pharmaceuticals, Inc. |
|
|
|
| Date: March
29, 2005 |
By: |
/s/ Carrie E.
Carlander |
| |
Name:
Carrie E. Carlander |
| |
Title:
Chief Financial Officer, Vice President, Finance, and
Treasurer |
EXHIBIT
INDEX
|
Exhibit |
Description |
|
99.1
|
Press
Release of the Company dated March 29, 2005.
|